Sinead M. Lougheed
R&d
Amsterdam, NH, Netherlands
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial.
Journal: Journal for immunotherapy of cancer
Published: January 28, 2025
Exploring the dynamics of T-cell responses: a combined approach using EdU incorporation and proliferation dye dilution assay.
Journal: Immunology and cell biology
Published: August 16, 2024
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.
Journal: Oncoimmunology
Published: July 20, 2023
A Reconstructed Human Melanoma-in-Skin Model to Study Immune Modulatory and Angiogenic Mechanisms Facilitating Initial Melanoma Growth and Invasion.
Journal: Cancers
Published: March 15, 2023
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation.
Journal: Science immunology
Published: July 20, 2022
Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8+ T Cells and Elevated β-Catenin Activation Compared with Squamous Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 23, 2019
Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression.
Journal: Oncoimmunology
Published: February 13, 2019
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Journal: Cancer immunology, immunotherapy : CII
Published: September 22, 2018
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
Journal: Cancer immunology, immunotherapy : CII
Published: June 06, 2018
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: February 13, 2018
Last Updated: 09/26/2026